ERG and prostate cancer: PTEN loss is observed more frequently in ERG-positive tumors, and PTEN-deficient prostate cancer has been shown to have an enhanced inflammatory infiltrate, with a greater density of T-cells [78] and a higher expression of immune-related genes [80].